
Arvinas Inc (ARVN) Stock Forecast & Price Target
Arvinas Inc (ARVN) Analyst Ratings
Bulls say
Arvinas Inc. demonstrates a positive outlook driven by the recent VERITAC-2 trial results, which showed a statistically significant median progression-free survival (mPFS) benefit in patients with ESR1 mutations, bolstering its competitive position in the biopharmaceutical landscape. The combination therapy of vepdeg with CDK4/6 inhibitors is supported by previous promising data, indicating a potential for differentiation and competitiveness, particularly if the mPFS exceeds four months for ESR1 mutant patients. Additionally, the trial data confirm a safe profile for vepdeg, with no dose-limiting toxicities or severe adverse events, reinforcing investor confidence in the therapeutic's efficacy and safety.
Bears say
Arvinas Inc. faces significant challenges that contribute to a negative outlook on its stock, primarily due to concerns regarding the limited benefit of its treatment candidates in certain patient populations, which could result in restrictive labeling and delayed timelines for meaningful clinical differentiation. Additionally, the anticipated clinical and commercial risks associated with various product candidates, such as vepdegestrant, ARV-102, and ARV-766, remain high, potentially impacting revenue estimates if these candidates fail to meet expectations. The lack of momentum for earlier line studies and uncertainty about the company's broader pipeline further exacerbate the potential for limited market opportunities against increasing competition.
This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.
Arvinas Inc (ARVN) Analyst Forecast & Price Prediction
Start investing in Arvinas Inc (ARVN)
Order type
Buy in
Order amount
Est. shares
0 shares